tradingkey.logo

Glaukos Corp

GKOS
112.520USD
-0.990-0.87%
Cierre 02/06, 16:00ETCotizaciones retrasadas 15 min
6.46BCap. mercado
PérdidaP/E TTM

Más Datos de Glaukos Corp Compañía

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.

Información de Glaukos Corp

Símbolo de cotizaciónGKOS
Nombre de la empresaGlaukos Corp
Fecha de salida a bolsaJun 25, 2015
Director ejecutivoBurns (Thomas William)
Número de empleados995
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 25
Dirección1 Glaukos Way
CiudadALISO VIEJO
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísUnited States of America
Código postal92656
Teléfono19493679600
Sitio Webhttps://www.glaukos.com
Símbolo de cotizaciónGKOS
Fecha de salida a bolsaJun 25, 2015
Director ejecutivoBurns (Thomas William)

Ejecutivos de Glaukos Corp

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Thomas William Burns
Mr. Thomas William Burns
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.51M
--
Mr. David F. Hoffmeister
Mr. David F. Hoffmeister
Independent Director
Independent Director
70.27K
+753.00%
Mr. Mark J. Foley
Mr. Mark J. Foley
Lead Independent Director
Lead Independent Director
57.52K
+1168.00%
Ms. Aimee S. Weisner, J.D.
Ms. Aimee S. Weisner, J.D.
Independent Director
Independent Director
49.85K
+623.00%
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Independent Director
Independent Director
36.91K
+727.00%
Dr. Tomas Navratil
Dr. Tomas Navratil
Chief Development Officer
Chief Development Officer
34.86K
+1544.00%
Dr. Gilbert H. (Gil) Kliman, M.D.
Dr. Gilbert H. (Gil) Kliman, M.D.
Independent Director
Independent Director
--
--
Mr. Joseph E. Gilliam
Mr. Joseph E. Gilliam
President, Chief Operating Officer
President, Chief Operating Officer
--
--
Dr. Leana S. Wen, M.D.
Dr. Leana S. Wen, M.D.
Independent Director
Independent Director
--
--
Ms. Denice M. Torres, J.D.
Ms. Denice M. Torres, J.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Thomas William Burns
Mr. Thomas William Burns
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.51M
--
Mr. David F. Hoffmeister
Mr. David F. Hoffmeister
Independent Director
Independent Director
70.27K
+753.00%
Mr. Mark J. Foley
Mr. Mark J. Foley
Lead Independent Director
Lead Independent Director
57.52K
+1168.00%
Ms. Aimee S. Weisner, J.D.
Ms. Aimee S. Weisner, J.D.
Independent Director
Independent Director
49.85K
+623.00%
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Independent Director
Independent Director
36.91K
+727.00%
Dr. Tomas Navratil
Dr. Tomas Navratil
Chief Development Officer
Chief Development Officer
34.86K
+1544.00%

Desglose de ingresos

Divisa: USDActualizado: mar., 6 de ene
Divisa: USDActualizado: mar., 6 de ene
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por negocioUSD
Nombre
Ganancia
Proporción
Glaucoma
110.25M
82.56%
Corneal Health
23.29M
17.44%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
101.45M
75.97%
International
32.09M
24.03%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Glaucoma
110.25M
82.56%
Corneal Health
23.29M
17.44%

Estadísticas de accionistas

Actualizado: sáb., 31 de ene
Actualizado: sáb., 31 de ene
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
13.59%
The Vanguard Group, Inc.
10.46%
Wellington Management Company, LLP
6.23%
PRIMECAP Management Company
3.92%
State Street Investment Management (US)
3.66%
Otro
62.13%
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
13.59%
The Vanguard Group, Inc.
10.46%
Wellington Management Company, LLP
6.23%
PRIMECAP Management Company
3.92%
State Street Investment Management (US)
3.66%
Otro
62.13%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
48.90%
Investment Advisor/Hedge Fund
35.43%
Hedge Fund
10.15%
Individual Investor
3.31%
Research Firm
2.10%
Pension Fund
2.05%
Sovereign Wealth Fund
1.32%
Bank and Trust
0.92%
Venture Capital
0.64%

Participación institucional

Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
678
58.37M
101.63%
-6.67M
2025Q3
653
61.34M
106.80%
+235.97K
2025Q2
638
61.06M
106.48%
+15.37K
2025Q1
643
60.20M
105.40%
-1.30M
2024Q4
610
59.75M
105.65%
+533.86K
2024Q3
567
57.47M
104.31%
-894.95K
2024Q2
545
56.86M
103.79%
-713.22K
2024Q1
509
54.47M
110.12%
-1.91M
2023Q4
480
53.71M
109.34%
-1.79M
2023Q3
475
52.90M
108.58%
-1.85M
Ver más

Actividad de los accionistas

Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BlackRock Institutional Trust Company, N.A.
7.81M
13.59%
-89.56K
-1.13%
Sep 30, 2025
The Vanguard Group, Inc.
6.03M
10.5%
-65.70K
-1.08%
Sep 30, 2025
Wellington Management Company, LLP
3.58M
6.23%
+336.27K
+10.36%
Sep 30, 2025
PRIMECAP Management Company
2.25M
3.92%
+425.79K
+23.29%
Sep 30, 2025
State Street Investment Management (US)
2.10M
3.66%
+14.00K
+0.67%
Sep 30, 2025
AllianceBernstein L.P.
1.73M
3.02%
+481.62K
+38.47%
Sep 30, 2025
Burns (Thomas William)
1.51M
2.63%
+3.07K
+0.20%
Dec 30, 2025
Geode Capital Management, L.L.C.
1.32M
2.29%
-14.51K
-1.09%
Sep 30, 2025
Columbia Threadneedle Investments (US)
1.27M
2.21%
+247.45K
+24.25%
Sep 30, 2025
Westfield Capital Management Company, L.P.
1.23M
2.14%
+63.79K
+5.46%
Sep 30, 2025
Ver más

ETFs relacionados

Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Invesco S&P SmallCap Health Care ETF
3.09%
Alger Weatherbie Enduring Growth ETF
2.07%
State Street SPDR S&P Health Care Equipment ETF
1.79%
ROBO Global Healthcare Technology & Innovation ETF
1.4%
State Street SPDR S&P 600 Small Cap Growth ETF
0.69%
Vanguard S&P Small-Cap 600 Growth Index Fund
0.65%
iShares S&P Small-Cap 600 Growth ETF
0.64%
iShares U.S. Medical Devices ETF
0.6%
OneAscent Enhanced Small and Mid Cap ETF
0.53%
State Street SPDR S&P SmallCap 600 ESG ETF
0.51%
Ver más
Invesco S&P SmallCap Health Care ETF
Proporción3.09%
Alger Weatherbie Enduring Growth ETF
Proporción2.07%
State Street SPDR S&P Health Care Equipment ETF
Proporción1.79%
ROBO Global Healthcare Technology & Innovation ETF
Proporción1.4%
State Street SPDR S&P 600 Small Cap Growth ETF
Proporción0.69%
Vanguard S&P Small-Cap 600 Growth Index Fund
Proporción0.65%
iShares S&P Small-Cap 600 Growth ETF
Proporción0.64%
iShares U.S. Medical Devices ETF
Proporción0.6%
OneAscent Enhanced Small and Mid Cap ETF
Proporción0.53%
State Street SPDR S&P SmallCap 600 ESG ETF
Proporción0.51%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos

División de acciones

Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
KeyAI